Details of Disease

General Information of Disease (ID: DISI8W45)

• Disease Name: Anaemia
• Disease Class: 3A90: Acute disease anaemia
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISI8W45: Anaemia
• ICD Code:
  ICD-11: ICD-11: 3A90
  ICD-10: ICD-10: D64.8
  Expand ICD-11: '3A9Z
  Expand ICD-10: 'D60-D64; 'D64; 'D64.9; 'D74; 'D74.8; 'D74.9; 'D75; 'D75.9
  Expand ICD-9: 2.80E+17
• Disease Identifiers:
  MONDO ID: MONDO_0002280
  MESH ID: D000740
  UMLS CUI: C0002871
  MedGen ID: 1526
  HPO ID: HP:0001903
  SNOMED CT ID: 271737000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Daprodustat	DMRNGD2	Approved	Small molecular drug	[1]
Luspatercept	DM715KM	Approved	NA	[2]
Peginesatide acetate	DM8JWOP	Approved	NA	[3]

This Disease is Treated as An Indication in 10 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AKB-6548	DM2EJM3	Phase 3	NA	[4]
BAY 853934	DM407I6	Phase 3	Small molecular drug	[5]
FG-4592	DM4XSQ2	Phase 3	Small molecular drug	[6]
JTZ-951	DM8FSPV	Phase 3	NA	[7]
ACH-4471	DMLVCZR	Phase 2	NA	[8]
FMX-8	DM15QDD	Phase 2	Recombinant protein	[9]
LY2928057	DMRDEKZ	Phase 2	NA	[10]
LY3113593	DMDFZK8	Phase 2	Antibody	[11]
PRS-080	DMNL6Y3	Phase 1/2	NA	[12]
ZYAN1	DM796RI	Phase 1	Small molecular drug	[10]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
12B9m	DM5IUN8	Preclinical	Antibody	[10]
JNJ-42905343	DMCNBHY	Preclinical	Small molecular drug	[10]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216951.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] ClinicalTrials.gov (NCT03242967) Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILOGY). U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT03418168) A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects (MIYABI PD). U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT01750190) A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT04027517) A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT03053102) Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH). U.S. National Institutes of Health.
• [9] ClinicalTrials.gov (NCT01873534) A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD. U.S. National Institutes of Health.
• [10] Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423.
• [11] ClinicalTrials.gov (NCT02604160) A Study of LY3113593 in Participants With Chronic Kidney Disease. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT02754167) Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients. U.S. National Institutes of Health.